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Abstract
Background: Assumptions underlying placebo controlled trials include that the placebo effect impacts on all study arms
equally, and that treatment effects are additional to the placebo effect. However, these assumptions have recently been
challenged, and different mechanisms may potentially be operating in the placebo and treatment arms. The objective of
the current study was to explore the nature of placebo versus pharmacological effects by comparing predictors of the
placebo response with predictors of the treatment response in a randomised, placebo-controlled trial of a
phytotherapeutic combination for the treatment of menopausal symptoms. A substantial placebo response was observed
but no significant difference in efficacy between the two arms.
Methods: A post hoc analysis was conducted on data from 93 participants who completed this previously published
study. Variables at baseline were investigated as potential predictors of the response on any of the endpoints of flushing,
overall menopausal symptoms and depression. Focused tests were conducted using hierarchical linear regression
analyses. Based on these findings, analyses were conducted for both groups separately. These findings are discussed in
relation to existing literature on placebo effects.
Results: Distinct differences in predictors were observed between the placebo and active groups. A significant difference
was found for study entry anxiety, and Greene Climacteric Scale (GCS) scores, on all three endpoints. Attitude to
menopause was found to differ significantly between the two groups for GCS scores. Examination of the individual arms
found anxiety at study entry to predict placebo response on all three outcome measures individually. In contrast, low
anxiety was significantly associated with improvement in the active treatment group. None of the variables found to
predict the placebo response was relevant to the treatment arm.
Conclusion: This study was a post hoc analysis of predictors of the placebo versus treatment response. Whilst this study
does not explore neurobiological mechanisms, these observations are consistent with the hypotheses that 'drug' effects
and placebo effects are not necessarily additive, and that mutually exclusive mechanisms may be operating in the two
arms. The need for more research in the area of mechanisms and mediators of placebo versus active responses is
supported.
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Background
The placebo-controlled trial is considered the gold stand-
ard among clinical research designs. The challenge of rig-
orous scientific research is to accurately determine the
specific effect of an intervention over and above the pla-
cebo effect, (also referred to as 'non-specific effects', or
'context effects'). Failure to do so may result in the rejec-
tion of the intervention as ineffective as a potential treat-
ment, as any benefits are ascribed to a placebo effect. We
question this approach and suggest that inappropriate
rejection of potentially viable treatments may be occur-
ring.
The underlying assumption of placebo-controlled trials is
that, for participants blinded as to their group assignment,
the placebo component affects all arms equally, with the
specific effect of the active intervention/s being additional
to the placebo effect in the intervention arm/s. This has
been termed the 'additivity' of effects. However, this
assumption has recently been challenged. It has been
argued by Kirsch and colleagues [1] that it is not a logical
necessity for the effects of the active treatment to be addi-
tive, or composed of the two components – the placebo
effect and the specific treatment effect (see Figure 1). In
support of their position they suggest that, if drug effects
and placebo effects are additive, then the pharmacological
effect of antidepressant drugs must be quite small [1],
since meta-analyses of antidepressant drugs have found
that 65% – 80% of the response to the drug is duplicated
in the placebo arm, including in long-term maintenance
studies [2-4]. They thus proposed that the effects may be
non-additive or only partially additive [1], suggesting dif-
ferent underlying mechanisms may be operating in the
placebo and pharmacological treatment arms.
One obvious conclusion from this observation is that
antidepressant medication does, in fact, exert a very small
pharmacological effect. Another possible explanation that
has been proposed is that different neurobiological mech-
anisms may be operating in the two arms. The placebo
may induce effects via psychological mechanisms only In
the absence of a pharmacological effect, while the active
treatment works through pharmacological mechanisms
alone [5]. Some support for this hypothesis is derived
from brain-imaging studies of depressed subjects, show-
ing that placebo and active treatments induce quite differ-
ent changes in brain function, despite exerting similar
benefits [6-8]. Similarly, neurophysiological research on
analgesia has suggested that expectation pathways, rather
than pain pathways, may be stimulated by placebo treat-
ment [9]. Expectation of reward has been shown to be at
least partly mediated by the dopaminergic system [10-13],
stimulation of which may be activated by the brain opioid
system [9,14,15]. There is evidence that both endogenous
opioids [16,17] and placebo-induced dopamine release
may be relevant to the placebo effect [18-20]. Participant-
related factors identified that may be responsible for the
effects produced by placebos include Pavlovian condi-
tioning resulting from prior exposure to the therapeutic
intervention, and the expectation of reward (clinical ben-
efit, in this case) [21].
In this setting, the current study analysed data from a pre-
viously published double-blind, placebo-controlled, RCT
that had found no significant effect over placebo on any
of the endpoints [22] for the study treatment, which was
therefore concluded to exert no more than placebo effects.
A comparison was made between predictors of the
response in the placebo arm and predictors of the
response to the active treatment. It was hypothesised that,
if the additivitiy assumption is correct, then the same var-
iables would predict the response in both groups.
Methods
This study was a post hoc analysis of data from an investi-
gation of 93 participants who completed a randomised,
placebo-controlled, double-blind trial. We have previ-
ously published the outcome data on efficacy of the ther-
apy [22] and predictors of the placebo response in the
placebo group only [23]. Here we extend this evaluation
to examine whether these predictors are also relevant to
the treatment arm, and include data from all study partic-
ipants. The original RCT had investigated the effect of a
phytotherapeutic combination, consisting of the herbs
Hypericum perforatum and Vitex agnus-castus, for menopau-
sal symptoms in late-perimenopausal and postmenopau-
sal women [22]. Following entry to the study, a two-week
'Drug effects and the placebo response: additive and nonaddi- tive models'[1] Figure 1
'Drug effects and the placebo response: additive and 
nonadditive models'[1]. Reprinted by permission of Else-
vier from 'Are drug and placebo effects in depression addi-
tive? by Kirsch, I. Biological Psychiatry 47(8):733–5. Copyright 
2000 by the Society of Biological Psychiatry.
Figure 1  ‘Drug effects and the placebo response: additive and nonadditive models.’ 1 Reprinted by 
permission of Elsevier from ‘Are drug and placebo effects in depression additive? by Kirsch, I.   
Biological Psychiatry 47(8):733-5. Copyright 2000 by the Society of Biological Psychiatry. BMC Medical Research Methodology 2009, 9:41 http://www.biomedcentral.com/1471-2288/9/41
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non-treatment run-in preceded the 16-week treatment
phase. Endpoints included flushing, overall menopausal
symptoms measured on the Greene climacteric scale
(GCS) and depressive symptoms measured on the Hamil-
ton Depression Inventory (HDI), both well-validated
widely available tools. The trial was approved by the
Human Research Ethics Committee at Royal Melbourne
Institute of Technology University.
Study intervention
As previously described [22], two Vitex agnus-castus tablets
or matching placebos were administered daily, in addi-
tion to three Hypericum perforatum tablets or matching pla-
cebos. The placebos were identical to the herbal tablets in
size, colour, coating, weight and packaging. Placebo tab-
lets comprised the excipients used in the active tablets;
these were cellulose, modified starch, magnesium stearate
and calcium hydrogen-phosphate. The daily dosage of the
herbs was 1,000 mg Vitex agnus-castus, and 5,400 mg
Hypericum perforatum. All tablets were manufactured
under the Code of Good Manufacturing Practice by Medi-
Herb Australia Pty Ltd.
Participants
Of the 93 women completing the trial, 47 had been ran-
domised to the active treatment group and 46 to the pla-
cebo arm (see Figure 2). All were late-perimenopausal or
postmenopausal women, aged 40 – 60 years. Details of
the inclusion and exclusion criteria have been published
previously [22]. Women were excluded if taking any med-
ication known to interact with either study herb.
Informed consent was obtained prior to study entry. Base-
line visits were conducted in a clinic setting and follow-up
contact by telephone. Medical clearance was obtained
from a general practitioner prior to inclusion in the trial.
Participants were requested to maintain their baseline die-
tary phytoestrogen intake during the trial.
Baseline data were collected for a range of variables, as
previously published [22]. These were tested individually
for their predictive ability. Measures administered at study
entry, baseline and end of treatment phase are shown in
Figure 3.
Statistical Analyses
Data were analysed using Statistical Package for Social Sci-
ence (SPSS) Version 16 with the assistance of a biostatisti-
cian. Data were analysed in two ways:
Firstly, focused tests of the difference between betas were
conducted for each of the three individual endpoints. To
do this, a series of hierarchical linear regression analyses
were conducted using grouping as a dichotomous varia-
ble. An interaction variable was created for grouping ×
predictor for each potential predictor variable. The inter-
action of grouping and predictor was examined. Secondly,
independent variables were assessed individually for their
ability to predict the response in each arm on the three
separate outcome measures. In each analysis, hierarchical
regression was conducted in order to control for the base-
line scores for the relevant outcome measures.
Response was defined as change in a favourable direction,
that is, decrease in severity of symptoms. Because total
GCS scores and GCS anxiety subscale scores were not
independent, these were not entered simultaneously into
a multiple regression analysis.
Results
Overall
The results of focused tests examining the interaction of
group and predictor are presented in table 1. A significant
difference was found in the predictive ability of anxiety at
study entry between the two arms for all three endpoints,
flushes R2 = 0.41, Std. β = 0.43, p = 0.001; GCS R2 = 0.29,
Std. β = 0.45, p = 0.002; HDI-17 scale R2 = 0.30, Std. β =
0.63, p < 0.001. Similarly, total GCS scores at study entry
as a predictor of the subsequent response varied signifi-
cantly between the two arms for all three endpoints of
flushing, R2 = 0.39, Std. β = -0.29, p = 0.012; overall men-
opausal symptoms measured on the GCS, R2 = 0.31, Std.
β = 0.43, p = 0.001; and depression measured on HDI-17,
R2 = 0.25, Std. β = 0.45, p = 0.001. Attitude to menopause
was found to differ significantly between the two groups
as a predictor of GCS scores, after controlling for baseline
scores, R2 = 0.27, Std. β = -0.34, p = 0.036.
Individual Arms
Variables found to have significant predictive ability in
the individual hierarchical linear regression analyses for
any of the three endpoints for the individual arms are pre-
sented in Table 2. A negative β co-efficient indicates that
more severe study entry scores were associated with
Participant flow Figure 2
Participant flow.
50
ALLOCATED TO 
PLACEBO
47 COMPLETED
PERIMENOPAUSAL 17 (36%) 
POSTMENOPAUSAL 23 (49%) 
UNKNOWN 7 (15%) 
46 COMPLETED
PERIMENOPAUSAL 14 (30%)
POSTMENOPAUSAL 23 (50%)
UNKNOWN 9 (20%) 
100
 PARTICIPANTS 
RECRUITED
50
ALLOCATED TO 
TREATMENT ARMBMC Medical Research Methodology 2009, 9:41 http://www.biomedcentral.com/1471-2288/9/41
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milder symptoms at week 16. The overall change observed
in GCS scores during non-treatment run-in was in the
direction of improvement in symptoms.
For the individual arms, predictors of response identified,
after controlling for baseline scores, were as follows.
Anxiety at study entry
Anxiety at study entry significantly predicted placebo response
on all the endpoints individually, with higher anxiety at
entry associated with lower scores at end of treatment phase:
flushes R2 = 0.33, Std. β = -0.28, p = 0.03; GCS R2 = 0.24, Std.
β = -0.29, p = 0.04; HDI-17 scale R2 = 0.34, Std. β = -0.66, p <
0.001. For the active treatment group, however, anxiety at
study entry predicted lack of response for flushing, R2 = 0.45,
Std. β = 0.28 p = 0.02, and depression, measured on the HDI-
17. R2 = 0.28, Std. β = 0.31, p = 0.03.
None of the other predictors of the placebo response was
relevant to the response in the active treatment arm (see
Table 2).
In the active treatment group, positive attitude to meno-
pause predicted response on GCS, R2 = 0.34, Std. β = -0.27,
p = 0.036.
Baseline severity of scores
For the placebo group, Pearson's bivariate correlations
revealed positive correlations between baseline scores and
subsequent percentage improvement during the treat-
ment phase for total GCS scores and anxiety subscale
scores. No relationship between severity of scores and
subsequent response was found for any of the endpoints
for the active treatment group.
Discussion
In the current study, there was a significant interaction
between predictors of the response to placebo and the
study intervention. Anxiety at study entry and overall men-
opausal symptoms at study entry (GCS scores) differed sig-
nificantly between the two arms as predictors of the
response on all three endpoints of flushing, overall meno-
pausal symptoms and depression. Attitude to menopause
Timeline of data collection22 Figure 3
Timeline of data collection22.
Figure 3  Timeline of data collection
22 
STUDY ENTRY            BASELINE            END                 POST-TREATMENT  
TREATMENT             FOLLOW-UP
FLUSHES, HDI, GREENE
FLUSHES
GREENE
0   2  18   26 
NO TREATMENT  TREATMENT PHASE NO TREATMENT 
HDI 
GREENE
FLUSHES
HDI 
GREENE
WEEK
Table 1: Differences between groups for predictors of week 16 endpoint scores, after controlling for baseline scores
Interaction of Group and Predictor Completing Participants
n = 93
Flushes Greene Climacteric Scale HDI-17
β (SE) p-value β (SE) p-value β (SE) p-value
GCS score, study entry 0.78 (0.30) 0.012 0.87 (0.24) 0.001 0.65 (0.18) 0.001
GCS anxiety, study entry 2.14 (0.65) 0.001 1.71 (0.54) 0.002 1.75 (0.40) <0.001
Attitude to menopause -2.99(3.53) 0.40 -6.03(2.83) 0.036 -3.43(2.14) 0.113
Unstandardised β-coefficient (SE)
Results obtained from hierarchical linear regression analysesBMC Medical Research Methodology 2009, 9:41 http://www.biomedcentral.com/1471-2288/9/41
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differed significantly in its predictive ability between the
two groups for the response on GCS scores. In terms of the
individual arms, there were distinct differences in predic-
tors of outcome observed between the placebo and active
groups. Anxiety at study entry predicted placebo response for
all the endpoints. In contrast, for flushing and depression
in the treatment arm, study entry anxiety significantly pre-
dicted a lack of response to treatment, and had no effect on
the Greene Climacteric scale scores. None of the other var-
iables that predicted the placebo response was relevant to
the treatment response. Improvement during non-treat-
ment run-in predicted subsequent improvement during the
treatment phase on GCS and HDI-17 depression scores for
the placebo arm. This trend was not mirrored in the active
treatment arm. For depression scores, older age at study
entry predicted placebo response, as did prior positive
experience with phytotherapy. However neither of these
variables significantly impacted on outcomes in the active
treatment arm. For the Greene Climacteric scale, baseline
severity of symptoms was positively correlated with per-
centage improvement across the treatment phase in the pla-
cebo group, but not in the active treatment group.
Previous researchers of a range of other conditions have
compared predictors of the responses in placebo and
active arms within the same study where effects between
the two arms differed [24-27]. Severity of symptoms at
baseline has been found to differentially predict the pla-
cebo and treatment responses, with more severe depres-
sion being less responsive to placebo but more responsive
to the pharmacological intervention [28]. Another study
on acute bipolar manic episodes found symptom severity,
age, number of previous hospitalisations to similarly pre-
dict the responses in both arms [25]. With regard to
change in symptom severity during run-in, significant
worsening of symptoms was associated with subsequent
placebo response, but not "drug response" in an analysis
of data from a functional dyspepsia study [29]. This con-
trasts with observations from the current study that
improvement during run-in predicted subsequent response
to placebo, but not to active treatment. However, to our
knowledge, no previous studies have examined data from
a RCT where superiority of 'active' treatment over placebo
was not established to test the hypothesis that the predic-
tors would be similar in the two arms.
In this study where efficacy of active and placebo were
equivalent, the implications of the finding that the predic-
tors of placebo response did not predict the treatment
response are intriguing. As mentioned above, it has previ-
Table 2: Predictors of week 16 endpoint scores for individual arms, after controlling for baseline scores
Placebo Group
n = 46
Active Treatment Group
n = 47
Flushes Greene 
Climacteric
Scale
HDI-17 Flushes Greene
Climacteric
Scale
HDI-17
 (SE) p-value  (SE) p-value  (SE) p-value  (SE) p-value  (SE) p-value  (SE) p-value
Age at trial 
start
0.03 
(0.28)
0.93 -0.26 
(0.24)
0.28 -0.39 
(0.17)
0.03 0.38 
(0.32)
0.25 -0.21 
(0.25)
0.41 0.23 
(0.19)
0.24
Previous 
Herb Med 
effective
-10.9 
(0.07)
0.63 -3.07 
(1.84)
0.10 -3.14 
(1.37)
0.03 -1.80 
(3.04)
0.56 -4.46 
(2.40)
0.07 -2.27 
(1.88)
0.23
Attitude to 
menopause
-0.63 
(2.18)
0.77 0.66 
(1.88)
0.73 -0.24 
(1.45)
0.87 -3.30 
(2.97)
0.27 -4.54 
(2.09)
0.04 -3.16 
(1.60)
0.055
GCS score, 
study entry
-0.53 
(0.17)
0.003 -0.43 
(0.16)
0.012 -0.38 
(0.13)
0.007 0.23 
(0.26)
0.37 0.38 
(0.26)
0.15 0.36 
(0.18)
0.03
GCS anxiety, 
study entry
-0.97 
(0.44)
0.03 -0.82 
(0.39)
0.04 -0.33 
(0.32)
<.001 1.16 
(0.47)
0.016 0.65 
(0.44)
0.14 0.68 
(0.31)
0.02
Change in 
GCS scores 
during run-in
-0.02 
(0.04)
0.59 -0.15 
(0.06)
0.013 -0.07 
(0.02)
0.005 -0.04 
(0.08)
0.68 0.13 
(0.08)
0.13 -0.07 
(0.05)
0.15
Unstandardised β-coefficient (SE)
Results obtained from hierarchical linear regression analysesBMC Medical Research Methodology 2009, 9:41 http://www.biomedcentral.com/1471-2288/9/41
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ously been suggested that the assumption of additivity of
effects that underlies the practice of using placebos may
not be a logical necessity [1]. It is possible that psycholog-
ical mechanisms may operate in the placebo arm only in
the absence of pharmacological effects, whereas effective
interventions activate pharmacological mechanisms to
the exclusion of psychological mechanisms [5]. Although
it is generally accepted that there is a placebo component
in the response to the active treatment when participants
are blinded, the hypothesis of non-additivity implies that
the pharmacological effects of an active intervention
could override the psychologically-activated placebo com-
ponent completely or partially. Essentially, the trial partic-
ipants would experience either placebo or physiological
intervention effects, but not both. If shown to be correct,
this would invalidate the assumption that intervention
effects are additive to placebo effects.
To our knowledge, no evidence exists from neurobiologi-
cal studies of differential mechanisms operating in rela-
tion to menopausal symptoms, although there is some
support for this phenomenon in relation to depression [6-
8]. As depression, measured on the Hamilton Depression
Inventory and the Greene Climacteric subscale, was one of
endpoints of the current study, different mechanisms
operating in the two arms in the current study cannot
entirely be ruled out.
It is interesting to note that higher anxiety at study entry
was a significant predictor of the placebo response, but
predicted lack of response to active treatment. This sup-
ports the proposition that psychological factors are rele-
vant to the placebo response, at least as moderators, if not
mediators. The observation that improvement during
non-treatment run-in predicted placebo response on two
of the three endpoints, but did not predict treatment
response, is consistent with the proposal that placebo-
induced mechanisms, such as the release of endogenous
opioids, may be activated in the anticipatory phase of the
placebo response [15] and hence during therapist-patient
or investigator-participant interaction [9]. The variance in
the predictors of placebo and active response observed in
the current study is consistent with the hypothesis that
different underlying mechanisms may be operating in pla-
cebo and treatment arms.
Strengths of the study include the investigation of study
entry scores (2 weeks prior to commencement of run-in),
in preference to baseline scores, as potential predictors of
the placebo response. The effect on psychological mecha-
nisms of enrollment in a clinical trial would be expected
to occur from the point of study entry, with the initiation
of investigator-participant interaction and other context
effects, rather than from initiation of the intervention [9].
However, because pharmacological effects of the interven-
tion would only be observable from the point of adminis-
tration of the intervention (see Figure 3), baseline scores
were controlled for in the analysis.
A limitation in the interpretation of these findings is that
there is no evidence, to our knowledge, supporting this
phytotherapeutic combination as an effective treatment
for menopausal symptoms. Therefore, a known pharma-
cological effect for this intervention in the treatment of
menopausal symptoms has never been established. This
study was a post hoc analysis of data from an RCT and as
such, was not designed to explore neurobiological mech-
anisms. Thus, no definite conclusions can be drawn
regarding any different mechanisms of action. Other pos-
sible limitations include the relatively small sample size,
the use of exclusively subjective outcome measures, and
the single scale of measurement for improvement during
non-treatment run-in.
Conclusion
In randomised, placebo-controlled clinical trials, greater
understanding of the placebo response is needed to accu-
rately dissect out placebo versus intervention effects. In
order to conclude that a pharmacological intervention is
ineffective if found not  to be superior to placebo, it is
essential to be confident that i) the placebo has no specific
effect for the condition being examined, and ii) that the
effects of the placebo and active intervention are com-
pletely additive, i.e. that subtracting the placebo effect
from the treatment effect leaves the active intervention
effect. The assumption of additivity has previously been
questioned by other authors [1]. Early research on neuro-
anatomical and neurobiological mechanisms, primarily
in the area of analgesia, suggests that placebo and phar-
macological interventions may activate mutually exclu-
sive pathways. The current findings could be explained in
light of the theory of non-additivity. Further research is
warranted into the neurophysiological basis of the pla-
cebo response to investigate the validity of the assump-
tion of additivity. If this assumption were shown to be
incorrect, it would have significant implications for the
interpretation of results from placebo-controlled RCTs.
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